Adjuvant and definitive radiation therapy for primary carcinoma of the vagina using brachytherapy and external beam radiation therapy.
Adjuvant and definitive radiation therapy for primary carcinoma of the vagina using brachytherapy and external beam radiation therapy.
复制标题
DOI：
10.5114/jcb.2013.36177
复制
发表时间：
2013-06
影响因子：
1.4
通讯作者：
Bradley K
中科院分区：
文献类型：
--
作者：
Platta CS;Anderson B;Geye H;Das R;Straub M;Bradley K
报告接受阴道近距离放射治疗和/或外射束放射治疗（EBRT）治疗原发性阴道癌的患者的结局。在1983年至2009年期间，63例患者在一个三级中心接受了近距离放射治疗和/或EBRT治疗原发性阴道肿瘤。通过病历审查收集患者数据。采用Kaplan-Meier法计算精确的盆腔局部控制（LC）、无病生存期（DFS）、总生存期（OS）和严重晚期毒性发生率。根据不良事件通用术语标准第3版（CTCAE v3.0）对急性和晚期毒性进行评分。中位随访时间为44.2个月。与局部晚期疾病患者（III期和IVA期）相比，早期疾病患者（I期和II期）的5年OS显著改善（73.3% vs. 34.4%，p = 0.032）。阴道受累超过1/3的患者的预后明显差于阴道受累1/3或更少的患者，后者在5年时上级DFS（84.0 vs. 52.4%，p = 0.007）和LC（86.9 vs. 60.4%，p = 0.018）更优。年龄、组织学和近距离放射治疗技术不影响治疗结果。5年精算3级或以上毒性发生率为23.1%（95% CI：10.6-35.6%）。在这项分析中，同时化疗对结局或毒性没有影响。阴道癌治疗的成功主要取决于疾病的分期，但其他因素，如阴道受累的程度和肿瘤的位置显着影响结果。阴道癌的放射治疗产生了可接受的结果与合理的毒性率。这种罕见的恶性肿瘤的管理需要一个多学科的方法，以适当优化治疗。
To report the outcomes of patients receiving vaginal brachytherapy and/or external beam radiation therapy (EBRT) for primary vaginal cancer. Between 1983 and 2009, 63 patients received brachytherapy and/or EBRT for primary tumors of the vagina at a single tertiary center. Patient data was collected via chart review. The Kaplan-Meier method was used to calculate actuarial pelvic local control (LC), disease-free survival (DFS), overall survival (OS), and severe late toxicity rates. Acute and late toxicities were scored according to the Common Terminology Criteria for Adverse Events version 3 (CTCAE v3.0). Median follow up was 44.2 months. Patients with early stage disease (stages I and II) had significantly improved 5-year OS when compared to patients with locally advanced disease (stages III and IVA) (73.3 vs. 34.4%, p = 0.032). Patients with greater than 1/3 vaginal involvement had significantly worse prognosis than patients with tumors involving 1/3 or less of the vagina, with the later having superior DFS (84.0 vs. 52.4%, p = 0.007) and LC (86.9 vs. 60.4%, p = 0.018) at 5-years. Age, histology, and brachytherapy technique did not impact treatment outcomes. The 5-year actuarial grade 3 or higher toxicity rate was 23.1% (95% CI: 10.6-35.6%). Concurrent chemotherapy had no impact on outcomes or toxicity in this analysis. Success of treatment for vaginal cancer depends primarily on disease stage, but other contributing factors such as extent of vaginal involvement and tumor location significantly impact outcomes. Treatment of vaginal cancer with primary radiotherapy yields acceptable results with reasonable toxicity rates. Management of this rare malignancy requires a multidisciplinary approach to appropriately optimize therapy.
登录
查看更多内容
影响因子：
5.7
作者：
de Crevoisier, Renaud;Sanfilippo, Nicholas;Haie-meder, Christine
通讯作者：
Haie-meder, Christine
DOI：
10.1186/1748-717x-3-7
发表时间：
2008-02-13
期刊：
Radiation oncology (London, England)
影响因子：
--
作者：
Beriwal S;Heron DE;Mogus R;Edwards RP;Kelley JL;Sukumvanich P
通讯作者：
Sukumvanich P
影响因子：
3.1
作者：
Seeger, AR;Windschall, A;Strnad, V
通讯作者：
Strnad, V
DOI：
10.1016/0360-3016(95)02394-1
发表时间：
1996-07-15
影响因子：
7
作者：
Chyle, V;Zagars, GK;Delclos, L
通讯作者：
Delclos, L
DOI：
10.1016/s0360-3016(98)00530-6
发表时间：
1999-04-01
影响因子：
7
作者：
Perez, CA;Grigsby, PW;Lockett, MA
通讯作者：
Lockett, MA